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KESAN EKSTRAK Hydrocotyle sibthorpioides Lam. TERHADAP PERENCATAN 
DENGGI VIRUS 2 SECARA In Vitro 
ABSTRAK 
Selama beribu tahun, amalan perubatan tradisional menggunakan tumbuh-
tumbuhan dan herba telah berkesan dalam merawat pelbagai jangkitan peyakit. Walau 
bagaimanapun, setelah berdekad usaha pencarian dijalankan, tiada antivirus yang terbukti 
berkesan untuk merawat jangkitan denggi virus (DENV) dan usaha ke arah pembangunan 
vaksin denggi terhalang oleh beberapa faktor utama seperti jenis serotip yang berbeza. 
Oleh itu, tujuan penyelidikan ini dijalankan adalah untuk mengkaji potensi antivirus di 
dalam tumbuhan Hydrocotyle sibthorpioides Lam. (H.sibthorpioides) terhadap jangkitan 
DENV-2 secara in-vitro. Tiga sel telah dipilih untuk tujuan kajian iaitu sel Vero, sel 
C6/36, dan sel HepG2.  
H.sibthorpioides telah diekstrak menggunakan dua pelarut berbeza, air dan 
metanol. Ujian ketoksikan telah dijalankan untuk menilai dan menentukan dos tertinggi 
ekstrak H.sibthorpioides yang mampu diterima oleh sel-sel yg dikaji. Hasil ujian 
menunjukkan ekstrak methanol H.sibthorpioides adalah lebih toksik berbanding ekstrak 
air H.sibthorpioides. Sel Vero mempunyai daya toleransi yang lebih luas terhadap ekstrak 
H.sibthorpioides diikuti oleh sel C6/36 dan sel HepG2. Asai antivirus telah dijalankan 
dalam dua peringkat rawatan yang berbeza, rawatan sebelum dan selepas infeksi untuk 
menilai kesan pencegahan dan terapeutik H.sibthorpioides terhadap replikasi DENV-2. 
Pemerhatian dijalankan terhadap perubahan morfologi dan kesan sitopatik (CPE), diikuti 
 xviii 
 
dengan pengesanan virus antigen menggunakan IFA dan seterusnya penilaian titer virus 
menggunakan asai plak dan qRT-PCR. 
Hasil kajian menunjukkan bahawa ekstrak H.sibthorpioides mempunyai aktiviti 
pencegahan yang rendah terhadap replikasi DENV-2 di dalam sel Vero tetapi tidak di 
dalam sel C6/36. Pra rawatan sel Vero menunjukkan ekstrak air H.sibthorpioides 
mempunyai 2 % - 44 % kesan perlindungan terhadap DENV-2 manakala 18 % - 30 % 
kesan perlindungan dilihat apabila ekstrak methanol H.sibthorpioides digunakan. 
Sebaliknya, secara umum, pra rawatan H.sibthorpioides ke atas sel C6/36 mempunyai 
kesan perlindungan yang minimum terhadap infeksi DENV-2. Hanya beberapa kepekatan 
H.sibthorpioides memberikan 5 % - 13 % kesan perencatan yang tidak signifikan pada sel 
C6/36. 
Rawatan selepas infeksi sel Vero yang dijangkiti dengan DENV-2 menggunakan 
ekstrak methanol H.sibthorpioides mempunyai kesan terapeutik yang lebih tinggi 
berbanding rawatan ekstrak air H.sibthorpioides. Replikasi DENV-2 direncatkan 
sebanyak 6 % - 31 % apabila pelbagai kepekatan ekstrak air H.sibthorpioides digunakan, 
manakala perencatan titer sebanyak 2 % - 42 % dicapai dengan rawatan ekstrak metanol 
H.sibthorpioides. Yang mengejutkan, rawatan selepas infeksi ke atas sel C6/36 
menyebabkan peningkatan replikasi DENV-2.  Peningkatan replikasi DENV-2 sebanyak 
7 % - 59 % dilihat dalam sel C6/36 yang dijangkiti dan telah dirawat dengan ekstrak air 
dan metanol H.sibthorpioides. 
 xix 
 
Asai antivirus telah dilanjutkan di dalam sel HepG2 dan hasil kajian menunjukkan 
bahawa ekstrak metanol H.sibthorpioides adalah lebih baik berbanding ekstrak air 
H.sibthorpioides dalam mengurangkan replikasi DENV-2. Rawatan selepas infeksi 
terhadap DENV-2 menggunakan ekstrak H.sibthorpioides menunjukkan potensi antivirus 
yang lebih baik berbanding rawatan pembunuhan dan rawatan serentak dalam sel HepG2. 
Kesimpulannya, H.sibthorpioides mempunyai kesan yang berbeza terhadap replikasi 
DENV-2 bergantung kepada jenis rawatan, jenis pelarut dan jenis sel yang digunakan; dan 
ini memberikan pemahaman lanjut tentang sifat kegunaan perubatan tumbuhan ini 
terhadap replikasi DENV-2. Kajian lanjut harus dijalankan untuk mengenalpasti kompaun 
yang terlibat dan bagaimana aktiviti antivirus itu berlaku. 
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THE EFFECT OF Hydrocotyle sibthorpioides Lam. EXTRACT ON DENGUE 
VIRUS 2 INHIBITION In Vitro 
ABSTRACT 
For thousands of years the practice of traditional medicine, using plant and herbs, 
has been effective in the treatment of various infections. Despite decades of efforts, there 
is no proven effective antiviral for DENV infection and attempts at vaccine development 
have been hampered by several major obstacles e.g different serotypes. The aim of this 
study therefore was to investigate the potential antiviral activity of Hydrocotyle 
sibthorpioides Lam. (H.sibthorpioides) towards DENV-2 infection in-vitro in three cell 
lines, Vero cells, C6/36 cells and HepG-2 cells. 
The H.sibthorpioides was extracted using two different solvents, water and 
methanol. Toxicity test were initially performed to evaluate and determine the highest 
tolerable dose of H.sibthorpioides extracts in the tested cell lines. The H.sibthorpioides 
methanolic extract was found to be more toxic than the water extract. Vero cells had a 
wider tolerance range to H.sibthorpioides extracts followed by C6/36 and HepG-2 cells. 
Antiviral assays were performed in two different stages, pre- and post-treatment to 
evaluate the H.sibthorpioides prophylactic and therapeutic effects on DENV-2 replication. 
The activities were scored by observing the morphological changes and CPE appearances, 
followed by detection of viral antigen by IFA and quantitation of viral titres by either 
plaque assay or qRT-PCR.  
 xxi 
 
The results demonstrated that H.sibthorpioides extracts possess mild prophylactic 
activity against DENV-2 replication in Vero cells but not in C6/36 cells. Pre-treatment of 
Vero cells showed that H.sibthorpioides pretreatment had 2 % - 44 % protective effect 
against DENV-2 in Vero cells using water extract, while 18 % - 30 % protective effect 
were seen when H.sibthorpioides methanolic extract was used. On the contrary, in general, 
H.sibthorpioides pre-treatment on C6/36 cells had low to no cellular protective effect 
against DENV-2 infection. Only few concentrations of H.sibthorpioides caused 5 % - 13 
% inconsequential inhibition on C6/36 cells  
The post treatment of DENV-2 infected-Vero cells with H.sibthorpioides 
methanolic extract presented higher therapeutic effect when compared with the 
H.sibthorpioides water extract. The DENV-2 viral replication was inhibited by 6 % - 31 
% when various concentrations of H.sibthorpioides water extract were used, while 2 % – 
42 % of DENV-2 titre reduction was seen in Vero cells post treated with H.sibthorpioides 
methanolic extract. Surprisingly, post treatment of C6/36 cells resulted in an enhancement 
of DENV-2 replication. An enhancement effect of DENV-2 by 7 % - 59 % was seen in 
infected-C6/36 cells post treated with H.sibthorpioides water and methanolic extracts. 
The antiviral assay was further extended in HepG-2 cells and the results 
demonstrated that the methanolic extract of H.sibthorpioides was better than the water 
extract in reducing DENV-2 replication. Post treatment of H.sibthorpioides extracts 
against DENV-2 showed more potent antiviral activity followed by virucidal treatment 
and concurrent treatment in HepG2 cells. As a conclusion, H.sibthorpioides had variable 
effects on DENV-2 replication, depending on treatment types, solvent types and cell lines 
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used; providing important novel insight on the phytomedicinal properties of the plant on 
DENV. Further studies are needed to verify which compounds could be responsible and 
how they exert their antiviral effects
  1 
CHAPTER ONE 
LITERATURE REVIEW 
1.1 Overview of dengue 
Dengue fever (DF), the most prevalent arthropod-borne viral illness in humans, is 
caused by dengue virus (DENV). Dengue is a one disease entity with different clinical 
presentations and often with unpredictable clinical evolution and outcomes (WHO, 2009). 
Originally, dengue virus infections occurred mainly as epidemics in tropical and 
subtropical countries, but over time, with increasing globalisation and the geographic 
spread of inhabitants of Aedes aegypti and Aedes albopictus mosquitos, dengue virus 
infection has steadily penetrated every corner of the world (Noisakran et al., 2010).  
1.1.1 Disease burden 
Dengue is a worsening global health problem. In 19th century, dengue was 
considered a sporadic disease that caused epidemics at long intervals, a reflection of the 
slow pace of transport and limited travel at that time and today in contrast, dengue ranks 
as the most important mosquito-borne viral disease in the world (WHO, 2012). According 
to the World Health Organization report, there are 50 million dengue infections and 500 
000 cases of dengue haemorrhagic fever (DHF) leading to hospitalisation each year. 
In Malaysia, dengue cases have risen alarmingly across the country this year, with 
data showing a 269% rise in the disease from January till May 2014 as compared to the 
same period last year (KKM, 2014). The number of cases reported annually to WHO 
ranged from 0.4 to 1.3 million in the decade 1996 – 2005. Underreporting and 
misdiagnoses are major obstacles to understanding the full burden of dengue and as an 
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infectious disease, the number of cases varies substantially from year to year (WHO, 
2009). 
Bhatt et al. (2013) estimated that there were 96 million apparent dengue infections 
in 2010 (Table 1.1) with Asia bore 70% of this burden, and is characterised by large 
swathes of densely populated regions coinciding with very high suitability for disease 
transmission. Recent studies have estimated annual economic burden of dengue in specific 
countries of Southeast Asia using the average reported cases between 2001 – 2005, in 
Cambodia, Malaysia and Thailand were at least US$ 3.1 (± 0.2), US$ 42.4 (± 4.3), and 
US$ 53.1 (± 11.4) million respectively (Shepard et al., 2013). Dengue inflicts all levels of 
society but the burden may be higher among the poorest who grow up in communities 
with inadequate water supply and solid waste infrastructure (WHO, 2009). 
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Table 1.1: Estimated burden of dengue in 2010, by continent (adapted from Bhatt et al. 
(2013)) 
 Apparent 
Millions  (credible interval) 
Inapparent 
Millions (credible interval) 
Africa 15.7 (10.5 – 22.5) 48.4 (34.3 – 65.2) 
Asia 66.8 (47.0 – 94.4) 204.4 (151.8 – 273.0) 
Americas 13.3 (9.5 – 18.5) 40.5 (30.5 – 53.3) 
Oceania 0.18 (0.11 – 0.28) 0.55 (0.35 – 0.82) 
Global 96 (67.1 – 135.6) 293.9 (217.0 – 392.3) 
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1.1.2 Epidemiology 
More than 100 countries are endemic, primarily affecting 2.5 billion inhabitants in 
the tropical and subtropical region (Figure 1.1) (WHO, 2009). It is estimated that about 
2.5 billion individuals, a staggering 40% of the world population, inhabit areas where 
there is a risk of transmission of DF and that disease burden has increased at least fourfold 
in the last three decades (Guzman and Istúriz, 2010). 
Dengue virus sustains in Asia and Africa probably through vertical transmission 
in mosquitoes and with regular amplification in non-human primates. The vector has 
adapted itself to survive in close vicinity to human settlement and is found predominantly 
between latitudes 350 N and 350 S throughout the globe (Kumar et al., 2010).  
Knowledge of the geographical distribution and burden of dengue is essential for 
understanding its contribution to global morbidity and mortality burdens, in determining 
how to allocate optimally the limited resources available for dengue control, and in 
evaluating the impact of such activities internationally (Bhatt et al., 2013) 
The factors responsible for the increasing importance of dengue as a global public 
health problem in the last decades are associated with demographic and social changes 
including unprecedented global population growth and the associated unplanned and 
uncontrolled urbanization, especially in tropical developing countries. Substandard 
housing, crowding, and deterioration in water, sewer, and waste management systems, 
intimately associated with unplanned urbanization have created ideal conditions for 
increased transmission of mosquito-borne diseases in tropical urban centres (De Paula and 
Fonseca, 2004). 
  5 
 
Figure 1.1: Countries/areas at risk of DENV transmission (dark-grey shading). The 
contour lines indicate the potential geographical limits of the northern and southern 
hemispheres for year-round survival of Aedes aegypti, the principal mosquito vector of 
DENVs (adapted from WHO (2009)). 
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1.1.3 Dengue virus 
DENV, the causative agent of dengue is a member of the family Flaviviridae with 
four distinct serotypes, dengue serotype 1, 2, 3 and 4 (DENV 1-4). It is a small, enveloped 
virus that contains a single-stranded, positive sense (messenger) RNA genome packaged 
inside a core protein, which is surrounded by an icosahedral scaffold and encapsidated by 
a lipid envelope (Noisakran et al., 2010). All four serotypes of DENV can be found 
worldwide.  
The relationships between the serotypes and transmission efficiency or disease 
expression are uncertain, but DENV-2 and DENV-3 are likely to contribute the most to 
disease severity and mortality (Guzman and Istúriz, 2010). Studies on the outbreaks in 
endemic areas, such as South East Asia revealed that a primary infection with DENV-1 or 
DENV-3 frequently resulted in a more severe disease than if DENV-2 or DENV-4 were 
the primary infection (Tang et al., 2012). Dengue virus also causes a wide range of clinical 
manifestations ranging from inapparent or mild febrile illness to severe and fatal 
haemorrhagic disease. 
1.1.4 Genome structure and viral proteins 
The distinction between dengue serotypes is based on their antigenicity. Flavivirus 
particles are spherical in shape, with a lipid envelope approximately 50 nm in diameter 
(Halstead, 2008). The genome is approximately 11 000 base pairs long, with 5’ capped 
and 3’-end usually not polyadenylated. The 5’ and 3’ non-coding regions are important 
for regulating viral replication. The termini of the genome contain untranslated regions 
(UTRs) that have key roles in the regulation of translation and genome replication. The 5’ 
  7 
UTR is relatively short and has a type І cap structure; the 3’ UTR contains several 
conserved RNA structures and lacks a terminal polyadenate tract (Murphy and Whitehead, 
2011). The gene order for structural proteins from the 5’ terminus is C-prM-E (Figure 
1.2). 
There are three structural proteins encoded in the 5’-one third of the viral genome: 
the capsid (C) protein forms the nucleocapsid shell protecting the viral genome, and the 
premembrane (prM), and envelope (E) proteins, both virion surface proteins embedded in 
the virion envelope. The main biological properties of the viruses are located in the E 
protein, including receptor binding, haemagglutination of erythrocytes, neutralising 
antibody induction, protective immune response, membrane fusion and virion assembly 
(Schoub and Blackburn, 2004).  The M- protein, which consists of seven antiparallel β-
strands, is important in the formation and maturation of the viral particles (Lai et al., 
2008). 
Seven non-structural (NS) proteins are encoded in the 3’-two thirds of the viral 
genome: NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5 (WHO, 2007).The structural 
proteins form the viral particle while the non-structural proteins participate in the 
replication of the RNA genome, virion assembly and invasion of innate immune response. 
Figure 1.2: Schematic representation of the organisation of the genes for Flavivirus  
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1.1.4.1 NS-1 protein 
NS-1 the first non-structural protein is synthesised in the rough endoplasmic 
reticulum as a hydrophilic, water-soluble, monomeric glycoprotein. It is a 48 000 
molecular weight glycoprotein containing two signals of the type, Asn-X-Ser/Thr, used 
for addition of N-linked carbohydrate. The NS-1 glycoprotein is produced by all 
flaviviruses and is secreted from mammalian cells. Dengue virus non-structural protein-1 
(NS1) is a secreted glycoprotein that is absent from viral particles but accumulates and 
resides in the supernatant and on the plasma membrane of cells during infection. It plays 
a critical role in viral RNA replication and has a central position in DENV pathogenesis.  
NS1 is strongly immunogenic and type-specific anti NS1 antibodies play a role in 
protection against disease and produces a very strong humoral response (WHO, 2007). 
Some of the NS1 protein is expressed as a soluble secreted form, which has been 
implicated to contribute to dengue viral propagation and the amount secreted is closely 
related to dengue viral titre. NS1 has an important yet unclear role in RNA replication, 
localizes to sites of RNA replication, and mutation of the N-linked glycosylation sites in 
NS1 can lead to dramatic defects in RNA replication (Lindenbach and Rice, 2007). 
The flavivirus nonstructural protein NS1 is expressed as three discrete species in 
infected mammalian cells: an intracellular, membrane-associated form essential for viral 
replication, a cell surface associated form that may be involved in signal transduction, and 
a secreted form (sNS1), the biological properties of which remain elusive. The DENV NS-
1 protein has also been intensively investigated as a potential target for vaccines and 
antiviral drugs (Amorim et al., 2014). 
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1.1.5 Virus replication 
The initial step of viral replication is the attachment of infectious viral particle to 
host cell. Recognition of the appropriate target cell and binding is mediated by viral 
surface or envelope proteins interacting with one or more cellular membrane proteins or 
other attachment factors on the plasma membrane. There are two methods by which 
attached virus may penetrate the host cells, the virion envelope may fuse with the plasma 
membrane with immediate deposition of the nucleocapsid into the cytoplasm, or the 
plasma membrane may invaginate, forming an endocytic vesicle around the still 
enveloped virus (Halstead, 2008).  
Since dengue viral genome can function as mRNA, if the viral RNA can be 
delivered into a cell’s cytoplasm through biologically active vesicles, translation and 
genome synthesis can occur accordingly (Noisakran et al., 2010). Two conditions are 
necessary for dengue virus fusion; an acidic environment and the presence of a negatively 
charged membrane (Zaitseva et al., 2010). Acidic conditions have been shown to activate 
a fusion protein, which leads to the deposition of the nucleocapsid within the cytoplasm.  
Since the dengue virus RNA genome has a positive sense, it must first be translated 
to make the RNA polymerase required for its replication. The polymerase transcribes the 
positive-strand RNA to negative-strand RNA, which then serves as template for additional 
positive strands. Viral RNA is then translated into a polyprotein that is processed by viral 
and cellular proteases and the viral NS proteins replicate the genome RNA (van Cleef et 
al., 2013) 
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Flavivirus assembly takes place at the endoplasmic reticulum (ER) where 
translation of the viral RNA and production of the viral polypeptide occurred. The 
structural glycoproteins prM and E localize to the luminal side of the ER and form an 
immature particle with prM and E in a heterodimeric complex. The cell’s protein synthesis 
produces new viral proteins that replicate the viral RNA and begin to form viral particles. 
Furin-mediated proteolysis of prM in the trans-Golgi network triggers rearrangement, 
homodimerization of E, and formation of the mature viral particle before release from the 
infected cell (Whitby et al., 2005). 
  The new mature viruses bud on the surface of the infected cell and are released by 
exocytosis and they are able to enter other white blood cells, such as monocytes and 
macrophages (Rodenhuis-Zybert et al., 2010). Released virus contain little, if any, prM; 
therefore, cleavage of prM must occur before or during exit from the cell. As the virus is 
transported through exocytic vesicle, and immediately prior to release, the prM protein is 
cleaved by a furin like protease to its mature M protein form, thus allowing the formation 
of E protein homodimer and activating the E protein for the pH dependent conformational 
changes which occur during subsequent attachment and entry into cells (Halstead et al., 
2005).  Immature, prM containing flavivirions are about 60-fold less infectious than 
mature virus. PrM may maintain the virion in a highly stable but relatively inert state. The 
final cleavage step makes the virus competent for infection but more labile. The processes 
of dengue viral replication have been simplified as shown in Figure 1.3.  
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Figure 1.3: Dengue virus replication. Virions are first adsorbed onto host cellular 
membranes and enter the cell by receptor mediated endocytosis. Fusion with lysosomes 
release the nucleocapsid, which disassembles to release the capped viral genomic RNA 
followed by translation and polyprotein processing which generate individual viral 
proteins that participate in viral replication or nucleocapsid formation. Virus particle 
formed following virion budding from the endoplasmic reticulum (ER). Host furin cleaves 
prM to generate a mature virion in the ER and Golgi complex. The virions is released 
following visicle fusion. (Adapted from Mukhopadhyay et al. (2005)). 
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1.2 Dengue transmission 
Principle hosts for dengue viruses are human and mosquito; mosquito remains 
infected throughout its life but human develops illness once they are infected. The four 
dengue viruses originated in monkeys and independently jumped to humans in Africa or 
Southeast Asia between 100 and 800 years ago (Halstead, 2008).  
Dengue viruses can be transmitted through the bite of female mosquitoes of Aedes 
aegypti, Aedes albopictus, Aedes polynesiensis and several species of the Aedes scutellaris 
complex. Each of these species has a particular ecology, behaviour and geographical 
distribution. Aedes aegypti is one of the most efficient vectors for arboviruses because it 
is highly anthropophilic, frequently bites several times before completing oogenesis, and 
thrives in close proximity to humans (WHO, 2009). 
In mosquito, after ingestion of a blood meal containing virus, the virus infects the 
epithelial cells lining the midgut, then escapes from the midgut epithelium into the 
haemocele and infects the salivary gland. The virus is secreted in the saliva, causing 
infection during probing (Chawla et al., 2014). The mosquito’s saliva containing dengue 
virus are transferred through the bite site when the infected mosquito is taking a blood 
meal  and then spreads to possible target tissues such as lymph nodes, spleen, bone marrow 
and liver (Halstead, 2008). 
  A female mosquito that takes blood meal from a person infected with dengue fever, 
during the initial 2-10 days febrile period becomes itself infected with the virus in the cells 
lining its gut (Vassil St. Goergiev, 2009). The mosquito may be infected with 2 different 
viruses without affecting the yield of either virus. 
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1.2.1 The vector 
Generally, mosquitoes spend the aquatic phase in immature stages and the 
terrestrial phase in the adult stage during which the events of mating, blood feeding and 
ovipositing take place. The life span of the adult mosquito usually depends on several 
factors: temperature, humidity, sex of the mosquito and time of the year (Alameda, 2001). 
The adult life of Aedes aegypti can range from 2 weeks to a month depending on 
environmental conditions and the life cycle can be completed within one and a half to 
three weeks as shown in Figure 1.4 (D.A. Bleijs, 2013).  
Larvae are mostly found in containers that may hold water, such as discarded tyres, 
buckets, flowerpots, wading pools and blocked rain gutters, and they can also be found in 
natural sites such as bromeliads, treeholes, and discarded coconut shells (Rigau-Pérez et 
al., 1998). In addition, the species prefers dark places with moisture for blood feeding and 
resting, such as in closets and under beds (Higa, 2011). They typically bite during the day, 
particularly in the early morning and in the evening (WHO, 2012). The feeding behaviour 
of the mosquito is characterised by easily interrupted feeding and repeated probing of one 
or several hosts. Because of this behaviour, the mosquito, if infective, may transmit DENV 
to multiple persons in a short time, even if they only probe without taking blood (Gubler, 
1998). 
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Figure 1.4: Life cycle of Aedes aegypti from egg to adult mosquito (adapted from D.A. 
Bleijs (2013)). 
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1.3 Clinical features of dengue 
Infection with   a DENV can produce a spectrum of clinical illness which ranges 
from a non-specific viral symptom to a severe and fatal haemorrhagic disease. Upon 
DENV infection, some individuals may develop mild disease with flu-like symptoms, 
whereas a few individuals may develop severe disease. Typically, people infected with 
dengue virus are asymptomatic or only have mild symptoms such as an uncomplicated 
fever. Young children may have an undifferentiated febrile disease with maculopapular 
rash while older children and adults have either a mild febrile syndrome or the classical 
incapacitating disease. 
After incubation period, the illness begins abruptly followed by the phases of 
febrile, clinical and recovery. The acute febrile phase of the illness, characterized by fever 
and myalgia, lasts 2-7 days and is often accompanied by facial flushing, skin erythema, 
generalised body ache and headache. Back pain, arthralgias and conjunctivitis may also 
occur (Whitehorn and Farrar, 2011). Fever, chills and malaise are common but nonspecific 
(Rothman, 2011). The earliest abnormality in the full blood count is a progressive decrease 
in total white cell count, which should alert the physician to a high probability of dengue. 
 Around the time of defervescence, an increase in the capillary permeability in 
parallel with increasing haematocrit levels may occur, and this marks the beginning of the 
critical phase. Progressive leukopenia followed by a rapid decrease in platelet count 
usually precedes plasma leakage. The degree of increase above the baseline haematocrit 
often reflects the severity of plasma leakage. Shock occurs when a critical volume of 
plasma is lost through leakage and it often preceded by warning signs (WHO, 2009).  
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A gradual reabsorption of extravascular compartment fluid takes place in the 
following 48-72 hours if the patient survives the critical phase. The patient’s general 
wellbeing improves, appetite returns, gastrointestinal symptoms abate and haemodynamic 
status stabilizes. The haematocrit stabilizes or may be lower due to the dilution effect of 
reabsorbed fluid. White blood count usually starts to rise soon after defervescence but the 
recovery of platelet count is typically later than that of white blood cell count (WHO, 
2009). Convalescence is accompanied by asthenia, and a full recovery often takes several 
weeks (Lim et al., 2013).  
1.4 Dengue case classification 
Clinical information from outbreaks of fatal dengue hemorrhagic fever in 
Southeast Asia children during the late 1960s, formed the basis for a dengue clinical 
classification published in World Health Organisation (WHO) guideline in 1975 and 
updated in 1997 (WHO, 1975; WHO, 1997). 
Symptomatic dengue virus infections were grouped into undifferentiated fever, 
dengue fever (DF) and dengue haemorrhagic fever (DHF). Difficulties in applying the 
criteria for DHF in the clinical situation, together with the increase in clinically severe 
dengue cases which did not fulfil the strict criteria of DHF, has led to the request for the 
classification to be considered (WHO, 2009). 
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1.4.1 The 1997 dengue case classification 
Since the 1970s, clinical dengue has been classified according to the WHO 
guidelines as DF and DHF. The 1997 WHO guidelines (Figure 1.5) classified dengue into 
DF, DHF (Grades 1 and 2) and dengue shock syndrome (DSS) (DHF Grades 3 and 4). DF 
is defined as a febrile illness with at least 2 clinical findings, including nausea, vomiting, 
headache, arthralgia, retro-orbital pain, rash, myalgia, haemorrhagic manifestations and 
leukopenia. The definition of DHF consists of 4 clinical criteria: fever, a haemorrhagic 
tendency (spontaneous bleeding or a positive tourniquet test result), thrombocytopenia 
(platelet count, ≤ 100 000 cells/mm3) and plasma leakage as shown by pleural effusion, 
ascites, or ≥ 20% haemoconcentration (WHO, 1997). 
Experience with this classification system has exposed a number of limitations and 
studies have demonstrated an overlap between case definitions of DF, DHF and DSS 
(Deen et al., 2006). The case definition fails to identify a significant proportion of severe 
dengue cases, for example, severe manifestations such as encephalopathy and hepatic 
failure which are not included in the DHF case definition. Reports have argued that the 
case definition of DHF is too rigid and too difficult to apply in primary care or resource-
limited settings (Balmaseda et al., 2005; Bandyopadhyay et al., 2006).  
 
  18 
 
Figure 1.5:  Manifestations of dengue virus infection (adapted from WHO (1997)). 
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1.4.2 The 2009 dengue case classification  
It then became apparent that the 1997 classification system is not universally 
applicable for appropriate clinical management, and in the 2006, the WHO Dengue 
Scientific Working Group recommended additional research into dengue diagnostics and 
triaging of patients for optimised clinical management and this has led to the re-
classification of dengue into dengue with and without warning signs and severe cases 
published in 2009 (Barniol et al., 2011; Hadinegoro, 2012) 
The 2009 classification (Figure 1.6) differs significantly from the previous 
classification in both conceptual and practical levels. The 2009 WHO dengue case 
classification classify dengue according to the levels of severity: dengue without warning 
signs; dengue with warning signs (abdominal pain, persistent vomiting, fluid 
accumulation, mucosal bleeding, lethargy, liver enlargement and increasing haematocrit 
with decreasing platelets); and severe dengue (dengue with severe plasma leakage, severe 
bleeding, or organ failure). Patients who recover following defervescence are considered 
to have non-severe dengue and those who deteriorate tend to manifest warning signs. 
Further deterioration is classified as severe dengue, although recovery is possible if 
appropriate and timely treatment is given (WHO, 2009). 
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Figure 1.6: The 2009 revised dengue case classification (adapted from WHO (2009)). 
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1.5 Host immune response 
To establish infection and replication in the hosts, flaviviruses have evolved a 
variety of strategies to modulate the host’s immune responses (Ye et al., 2013). They must 
evade or inhibit important elements of the innate immune system, namely the type І 
interferon (IFN) response, which negatively influences the subsequent development of 
antigen-specific adaptive immunity against those viruses. 
Innate immunity and type І IFN responses function as the first line of defence 
against viral infections, and responds by immediate protective defence mechanisms 
(Morrison et al., 2012). It involves the rapid recognition of pathogen associated molecular 
patterns (PAMP) in non-immune cells or cells of the innate immune system such as 
monocytes or macrophages, dendritic cells (DC), and natural killer (NK) cells. Hence the 
first barrier to overcome for successful viral infection is the rapid innate immune 
responses of the host, including type І IFNs, inflammatory cytokine, complement 
response, NK cell immunity, apoptosis and autophagy (Ye et al., 2013). Most viruses 
target these important elements to avoid being sensed or recognised in infected cells and 
to efficiently establish infection in the host. 
Adaptive immunity is triggered when a pathogen evades the innate immune system 
and generates a threshold level of antigen. The system consists of the humoral immune 
response (production of antibodies by B cells) and the cellular immune response (activities 
carried out by CD4+ and CD8+ T cells) (Ye et al., 2013). The lymphocytes of the adaptive 
immune system evolved to provide a more versatile means of defence which, in addition, 
provides increased protection against subsequent reinfection with the same pathogen. 
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Conversely, it may also play a critical role in the enhancement of disease severity in most 
patients with DHF/DSS (Murphy and Whitehead, 2011). 
  The cells of the innate immune system, however, also play a crucial part in the 
initiation and subsequent direction of adaptive immune responses, as well as participating 
in the removal of pathogens that have been targeted by an adaptive immune response.  
1.5.1 Primary and secondary dengue infections 
Two types of infections are caused by DENV, primary and secondary infection. 
Primary infection causes acute febrile illness known as DF and secondary infection causes 
more severe cases and results in DHF (Idrees and Ashfaq, 2013). Primary infection with 
any of the four serotypes results in a lifelong immunity to that serotypes, and temporary 
immunity to the others. However this temporary immunity usually wanes after 6 months, 
at which point an individual is susceptible to the other three DENV serotypes. Subsequent 
infections often leads to more severe secondary infection in the presence of heterologous 
dengue antibodies, which attributed to antibody dependent enhancement (Murrell et al., 
2011). 
The diagnosis of dengue fever can be made serologically by detecting anti-dengue 
IgM and/or IgG antibodies. Primary infections are characterized by an increase in dengue-
specific IgM antibodies four to five days after the onset of fever and by an increase in IgG 
antibodies (Chawla et al., 2014). In patients experiencing a primary infection, anti-dengue 
antibodies, initially of the IgM class, evolve relatively slowly.  The presence of IgM 
without IgG is suggestive of DENV primary infection. After a primary infection IgG 
reaches peak levels in the blood after 14-21 days.   
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Secondary responses are IgG antibodies which appear early, often during the 
febrile period, rise rapidly and are referred to as anamnestic (memory) responses. In 
subsequent re-infections, level peak earlier and the titres are usually higher. Both IgM and 
IgG provide protective immunity to the infecting serotype of the virus. IgM antibody is 
transient and generally disappears 30-90 days after onset of illness in primary infections 
while IgG antibody by contrast, persists for at least 60 years and probably for the life of 
the patient (Gubler, 2010).    
 
Figure 1.7: An Immune response to dengue infection (adapted from Guzman et al. 
(2010)) 
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1.6 Laboratory diagnosis of dengue 
Currently, dengue diagnosis is based on serology, viral isolation and viral RNA 
detection. Proof of a dengue infection depends on confirmatory reverse transcriptase-
polymerase chain reaction (RT-PCR), dengue serology, specific NS-1 antigen detection 
or viral isolation, if available (Whitehorn and Farrar, 2011). During the early stages of the 
disease, virus isolation, nucleic acid or antigen detection can be used to diagnose the 
infection. At the end of the acute phase of infection, serology is the method of choice for 
diagnosis. Enzyme linked immunosorbent assays (ELISA) are still the most widely used 
technique for serological diagnosis (De Paula and Fonseca, 2004). 
The differential diagnosis is extensive and varies depending on where the patient 
is seen, but would include malaria, typhoid, leptospirosis, scrub and murine typhus, 
septicaemia, other viral haemorrhagic fevers (eg. Ebola, Lassa fever), Chikungunya, and 
Rift Valley fever (usually without a rash) (Whitehorn and Farrar, 2011). 
1.7 Management and prevention of dengue 
To date, there are no available vaccine, chemoprophylactic or effective antiviral 
treatment for dengue. Thus far, the current prevention for dengue virus is by the prevention 
of its vector which is mosquito while medical supportive care is the recommended primary 
treatment for infected patients. Patients with DF require rest, oral fluids to compensate for 
losses via diarrhoea or vomiting, analgesics, and antipyretics for high fever.  
 Emergency control measures are based primarily on application of insecticides, 
and it is essential to monitor periodically the vector’s susceptibility to the insecticides 
